Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.Show others and affiliations
2015 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 11, no 12, p. 1470-1479, article id S1552-5260(15)00185-5Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.
METHODS: By cross-referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired.
RESULTS: Altogether, 77.2% had pathologic Aβ42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini-mental state examination score increased the likelihood of pathologic biomarkers.
DISCUSSION: About a quarter of clinically diagnosed AD patients did not have an AD-indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.
Place, publisher, year, edition, pages
Elsevier, 2015. Vol. 11, no 12, p. 1470-1479, article id S1552-5260(15)00185-5
Keywords [en]
Alzheimer's disease, Biomarkers, Cerebrospinal fluid, Diagnosis, Diagnostic criteria
National Category
Geriatrics Neurology
Identifiers
URN: urn:nbn:se:liu:diva-162692DOI: 10.1016/j.jalz.2015.04.007ISI: 000366721600008PubMedID: 26079415Scopus ID: 2-s2.0-84949827682OAI: oai:DiVA.org:liu-162692DiVA, id: diva2:1379229
2019-12-162019-12-162024-05-02Bibliographically approved